EDSA Edesa Biotech, Inc.
USHealthcareAs of 2026-07-09 16:00
Why EDSA matters now
Edesa Biotech, Inc. (EDSA) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.02 with -3.97% on the session and $67.6M in market capitalization; recent performance reads 1-month -38.49% and YTD +417.61%.
The latest financial table shown here is Q2 2026, with revenue of $0.00, net income of $-4.2M, and EPS of $-0.50. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.7%.
The latest indexable market news headline is "Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Nijhawan Pardeep filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.95
P/S
0.00
EV/EBITDA
-5.28
DCF Value
$2.00
FCF Yield
-11.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-82.3%
ROA
-84.3%
ROIC
-108.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-4.2M | $-0.50 |
| Q1 2026 | $0.00 | $-2.2M | $-0.28 |
| Q4 2025 | $0.00 | $-2.2M | $-0.32 |
| FY 2025 | $0.00 | $-7.2M | $-1.27 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
1.07
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.